🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

17 recruiting trials

for Resectable Stage II-III Non-Small Cell Lung Cancer (NSCLC)

A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC) NCT04302025Phase 238 sites📍 Duarte📍 Irvine📍 Los Angeles Genentech, Inc. · Tests: Alectinib, Entrectinib, Vemurafenib, Cobimetinib, Pralsetinib Effect of Infusion Timing on Pathologic Response to Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung Cancer NCT07251582Phase 32 sites📍 Changsha📍 Changsha Hunan Province Tumor Hospital · Tests: Time of Day-based Assignment for Infusion of Immune Checkpoint Inhibitor (e.g., toripalimab, or pembrolizumab) + platin… Neoadjuvant Therapy of SBRT Sequencial With Toripalimab and Chemotherapy in Resectable Stage II-III NSCLC Patients(neoR-TORCH) NCT06437977Phase 31 site📍 Shanghai Shanghai Chest Hospital · Tests: SBRT, Toripalimab A Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung Cancer NCT05913089Phase 210 sites📍 Beijing📍 Beijing📍 Beijing Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Tests: TQB2450 injection + Chemotherapy, TQB2450 injection + Anlotinib Hydrochloride Capsule Efficacy of Anti-CTLA-4 Antibody Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-III Non-Small Cell Lung Cancer NCT07410975Phase 21 site📍 Shanghai Shanghai Pulmonary Hospital, Shanghai, China · Tests: sintilimab+IBI310+chemotherapy Cryoablation Combined With Tislelizumab and Chemotherapy as Neoadjuvant and Adjuvant Therapy in Resectable Stage II-IIIB NSCLC NCT06939127Phase 21 site📍 Tianjin Tianjin Medical University Cancer Institute and Hospital · Tests: Neoadjuvant Cryoablation Combined with Tislelizumab and Chemotherapy, Surgery, Adjuvant tislelizumab A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer. NCT06284317Phase 342 sites📍 Camperdown📍 Penrith📍 St Leonards ETOP IBCSG Partners Foundation · Tests: Adjuvant durvalumab Comparison of Perioperative Immunotherapy, Adjuvant Immunotherapy or Neoadjuvant Immunotherapy for Resectable Stage II-IIIA NSCLC NCT07554846Phase 31 site📍 Shanghai Fudan University · Tests: Peroperative immunotherapy, Neoadjuvant immunotherapy, Adjuvant immunotherapy IBI363 (PD-1/IL-2α-bias) in Combination With Chemotherapy as Neoadjuvant Therapy in Initially Unresectable Stage III Non-Small Cell Lung Cancer NCT07408635Phase 21 site📍 Shanghai Shanghai Pulmonary Hospital, Shanghai, China · Tests: IBI363 + Chemotherapy Neoadjuvant Envafolimab Plus Disitamab Vedotin and Carboplatin in Resectable HER2-Mutant Non-Small-Cell Lung Cancer NCT06734182Phase 21 site📍 Guangzhou Guangdong Provincial People's Hospital · Tests: Envafolimab injections+intravenous Disitamab Vedotin+carboplatin IBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer NCT07122687Phase 21 site📍 Shenyang Innovent Biologics (Suzhou) Co. Ltd. · Tests: Pemetrexed, Cisplatin, IBI363, Carboplatin, Keytruda IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE) NCT05742607Phase 230 sites📍 St. Petersburg📍 Tampa📍 Chicago Innate Pharma · Tests: IPH5201 + durvalumab + standard chemotherapy A Study Comparing Neoadjuvant Chemoimmunotherapy and Immuno-consolidationafter Compared With Immunoconsolidation After Radical Chemoradiotherapy for Stage III Potentially Resectable NSCLC NCT06424899Phase 21 site📍 Hangzhou Zeng Jian · Tests: Adebrelimab, radical chemoradiotherapy, Platinum based chemotherapy Tislelizumab Combined With Anlotinib and Nab-paclitaxel in II-III Resectable Non-small Cell Lung Cancer : A Prospective, Single-Arm, Phase II Study NCT07089199Phase 21 site📍 Jinan Qilu Hospital of Shandong University · Tests: neoadjuvant therapy, Surgery, Adjuvant therapy PALACE: Cemiplimab Trial According to ctDNA Levels NCT06917573Phase 220 sites📍 Alicante📍 Elche📍 Badalona Fundación GECP · Tests: Cemiplimab, Carboplatin, Paclitaxel A Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(PANKU-Lung09) NCT07642024Phase 2, Phase 32 sites📍 Shanghai📍 Shanghai Sichuan Baili Pharmaceutical Co., Ltd. · Tests: BL-B01D1, Osimertinib, Carboplatin, Pemetrexed, Cisplatin A Trial of SHR-1316/Placebo in Combination With Chemotherapy in Patients With Resectable NSCLC NCT04316364Phase 37 sites📍 Beijing📍 Guangzhou📍 Zhengzhou Jiangsu HengRui Medicine Co., Ltd. · Tests: SHR-1316、Paclitaxel (Albumin Bound)、Carboplatin, SHR-1316、Chemotherapeutic, Placebo、Chemotherapeutic
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy